Medical Marijuana Inc (MJNA)
OTHER OTC:MJNA
Top Page
No summary available
Positive Factors
Strong Equity Base
A strong equity base provides financial stability and can support long-term growth initiatives, reducing reliance on external debt.
Negative Factors
Declining Revenue
Consistent revenue decline suggests challenges in market demand or competitive positioning, potentially impacting long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Base
A strong equity base provides financial stability and can support long-term growth initiatives, reducing reliance on external debt.
Read all positive factors
Medical Marijuana (MJNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.06M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-1.15
Revenue Growth-18.88%
EPS Growth87.50%
CountryUS
Employees91
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding10,282,333,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.04
Price to Sales (P/S)0.14
P/FCF Ratio2.08
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.26
Enterprise Value/Ebitda18.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medical Marijuana Business Overview & Revenue Model
Company Description
Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidi...
How the Company Makes Money
Medical Marijuana, Inc. generates revenue through multiple streams, primarily from the sale of hemp-derived CBD products. The company operates several subsidiaries that focus on different aspects of the cannabis market, including retail sales, dir...
Medical Marijuana Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.62M | 14.91M | 16.81M | 25.10M | 34.12M | 46.94M |
| Gross Profit | 10.58M | 11.66M | 11.25M | 18.46M | 26.86M | 37.73M |
| EBITDA | 151.01K | -73.98K | -4.72M | -14.94M | -4.04M | -95.03M |
| Net Income | -419.04K | -641.60K | -5.08M | -15.35M | -4.77M | -95.78M |
Balance Sheet | ||||||
| Total Assets | 67.97M | 67.83M | 69.55M | 68.92M | 80.72M | 84.32M |
| Cash, Cash Equivalents and Short-Term Investments | 973.83K | 1.03M | 674.22K | 736.51K | 5.45M | 6.30M |
| Total Debt | 2.94M | 2.85M | 3.70M | 7.65M | 4.80M | 10.20M |
| Total Liabilities | 17.60M | 18.03M | 19.63M | 14.32M | 11.58M | 19.00M |
| Stockholders Equity | 50.37M | 49.80M | 49.92M | 54.60M | 69.13M | 65.32M |
Cash Flow | ||||||
| Free Cash Flow | 692.49K | 977.30K | -6.90M | -17.61M | -4.50M | -95.95M |
| Operating Cash Flow | 692.49K | 977.30K | -2.54M | -14.75M | -4.48M | -95.95M |
| Investing Cash Flow | 203.42K | 408.58K | -2.67M | 6.17M | 1.86M | 93.17M |
| Financing Cash Flow | -395.54K | -384.13K | 5.15M | 3.89M | 1.77M | 2.87M |
Medical Marijuana Peers Comparison
UnderperformOutperform
Sector (51)
MJNA
Medical Marijuana
―
―
―
YCBD
cbdMD
0.70
-1.52
-68.47%
ADXN
Addex Therapeutics
6.48
-0.39
-5.68%
CERO
CERo Therapeutics Holdings
0.03
-15.37
-99.79%
AKAN
Akanda Corp
0.69
-16.03
-95.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―